Table 3.
Treatment related conditions of HIV positive mothers who delivered in HUCSH, 2018
| Characteristics | Frequency | Percent |
|---|---|---|
| HAART exposure (n = 252) | ||
| No | 39 | 15.5 |
| Yes | 213 | 84.5 |
| HAART initiated (n = 213) | ||
| During pregnancy | 23 | 10.8 |
| Before pregnancy | 190 | 89.2 |
| ART Regimen (n = 213) | ||
| TDF-3TC-EFV | 135 | 63.4 |
| AZT-3TC-NVP | 53 | 24.9 |
| TDF-3TC-NVP | 25 | 11.7 |
| Baseline CD4 count (cells/mm3) (n = 213) | ||
| < 200 | 69 | 32.4 |
| 201–350 | 59 | 27.7 |
| > 350 | 85 | 39.9 |
| CD4 level during the pregnancy (cells/mm3) (n = 213) | ||
| < 200 | 16 | 7.5 |
| 201–350 | 37 | 17.4 |
| > 350 | 160 | 75.1 |
| WHO clinical staging (n = 252) | ||
| Stage I | 217 | 86.1 |
| Stage II | 17 | 6.7 |
| Stage III | 11 | 4.4 |
| Stage IV | 7 | 2.8 |